Contact
searchSearch
HMP Global
Login
Quiz

FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer

12/10/2025

Related Content

News
Adding Atezolizumab to Chemoradiation Fails to Improve Outcomes for Limited-Stage SCLC
01/19/2026
Gina Tomaine
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and...
01/19/2026
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
Quiz
Evaluating Pembrolizumab Plus Chemotherapy in Extensive SCLC
12/17/2025
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed...
12/17/2025
Oncology
News
Durvalumab Plus Chemotherapy Shows Real-World Activity in Extensive-Stage SCLC
12/17/2025
Stephanie Holland
Results from the phase 3b CANTABRICO trial demonstrate that first-line durvalumab plus platinum-etoposide shows acceptable safety and clinically meaningful survival benefit in extensive-stage small cell lung cancer.
Results from the phase 3b CANTABRICO trial demonstrate that first-line durvalumab plus platinum-etoposide shows acceptable safety and clinically meaningful survival benefit in extensive-stage small cell lung cancer.
Results from the phase 3b...
12/17/2025
Oncology

Recent News

News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology
News
Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer
01/21/2026
Stephanie Holland
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/21/2026
Oncology
News
FDA Issues Draft Guidance on Use of MRD and Complete Response as End Points to Support Accelerated Approval in Multiple Myeloma
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
News
Adding Atezolizumab to Chemoradiation Fails to Improve Outcomes for Limited-Stage SCLC
01/19/2026
Gina Tomaine
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and...
01/19/2026
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
News
Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer
01/15/2026
Gina Tomaine
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with...
01/15/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Significantly Extends Progression-Free Survival in Advanced Desmoid Tumors
01/13/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial...
01/13/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use